Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Halfmann

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Med (New York, N.Y.)|March 22, 2022
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamstersKatherine McMahan, Victoria Giffin, Lisa H Tostanoski, et al.
Nature|January 19, 2007
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virusDarwyn Kobasa, Steven M Jones, Kyoko Shinya, et al.
Bioorganic & Medicinal Chemistry|September 12, 2025
Novel tricycle expanded purine nucleosides with pan-viral activityCéline Martin-Ghoteimi, Kyle A Davis, Rayane Ghoteimi, et al.
Frontiers in Microbiology|July 12, 2019
Isolation of Highly Pathogenic H5N1 Influenza Viruses in 2009-2013 in VietnamGongxun Zhong, Shufang Fan, Tiago J S Lopes, et al.
Research Square|July 27, 2021
Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikePatrick Wilson, Siriruk Changrob, Yanbin Fu, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
A broadly-neutralizing antibody against <i>Ebolavirus</i> glycoprotein that potentiates the breadth and neutralization potency of other antibodiesFrancesca R Donnellan, Vamseedhar Rayaprolu, Pramila Rijal, et al.
Med (New York, N.Y.)|May 19, 2022
Durability of immune responses to the BNT162b2 mRNA vaccineMehul S Suthar, Prabhu S Arunachalam, Mengyun Hu, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
SARS-CoV-2 D614G Variant Exhibits Enhanced Replication <i>ex vivo</i> and Earlier Transmission <i>in vivo</i>Yixuan J Hou, Shiho Chiba, Peter Halfmann, et al.
Npj Viruses|May 7, 2026
A broadly-neutralizing antibody against Orthoebolavirus glycoprotein that potentiates the breadth and neutralization of other antibodiesFrancesca R Donnellan, Vamseedhar Rayaprolu, Pramila Rijal, et al.
Research Square|January 10, 2024
Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membraneErica Saphire, Zhe Li Salie, Zunlong Ke, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Med (New York, N.Y.)|March 22, 2022
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamstersKatherine McMahan, Victoria Giffin, Lisa H Tostanoski, et al.
Nature|January 19, 2007
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virusDarwyn Kobasa, Steven M Jones, Kyoko Shinya, et al.
Bioorganic & Medicinal Chemistry|September 12, 2025
Novel tricycle expanded purine nucleosides with pan-viral activityCéline Martin-Ghoteimi, Kyle A Davis, Rayane Ghoteimi, et al.
Frontiers in Microbiology|July 12, 2019
Isolation of Highly Pathogenic H5N1 Influenza Viruses in 2009-2013 in VietnamGongxun Zhong, Shufang Fan, Tiago J S Lopes, et al.
Research Square|July 27, 2021
Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikePatrick Wilson, Siriruk Changrob, Yanbin Fu, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
A broadly-neutralizing antibody against <i>Ebolavirus</i> glycoprotein that potentiates the breadth and neutralization potency of other antibodiesFrancesca R Donnellan, Vamseedhar Rayaprolu, Pramila Rijal, et al.
Med (New York, N.Y.)|May 19, 2022
Durability of immune responses to the BNT162b2 mRNA vaccineMehul S Suthar, Prabhu S Arunachalam, Mengyun Hu, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
SARS-CoV-2 D614G Variant Exhibits Enhanced Replication <i>ex vivo</i> and Earlier Transmission <i>in vivo</i>Yixuan J Hou, Shiho Chiba, Peter Halfmann, et al.
Npj Viruses|May 7, 2026
A broadly-neutralizing antibody against Orthoebolavirus glycoprotein that potentiates the breadth and neutralization of other antibodiesFrancesca R Donnellan, Vamseedhar Rayaprolu, Pramila Rijal, et al.
Research Square|January 10, 2024
Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membraneErica Saphire, Zhe Li Salie, Zunlong Ke, et al.
Pageof 6